Lohmann Ebba, Welter Marie-Laure, Fraix Valérie, Krack Paul, Lesage Suzanne, Laine Sophie, Tanguy Marie-Laure, Houeto Jean-Luc, Mesnage Valérie, Pollak Pierre, Durr Alexandra, Agid Yves, Brice Alexis
INSERM, U679, Paris, France.
Mov Disord. 2008 Apr 15;23(5):740-3. doi: 10.1002/mds.21903.
Patients with parkin mutations are known to have slower PD progression and a better response to levodopa at lower doses than patients with idiopathic Parkinson's disease. To determine the effects of deep brain stimulation (DBS) on such patients, we have compared the follow-up after surgery of 7 patients with one parkin mutation, 7 patients with two parkin mutations, and 39 patients without parkin mutations. Twelve to 24 months after neurosurgery, the daily doses of levodopa equivalent were significantly lower in patients with two parkin mutations, indicating that these patients benefit from DBS, and they might have more durable results.
已知携带帕金基因突变的患者帕金森病进展较慢,与特发性帕金森病患者相比,在较低剂量左旋多巴治疗时反应更好。为了确定深部脑刺激(DBS)对此类患者的影响,我们比较了7例携带一个帕金基因突变的患者、7例携带两个帕金基因突变的患者以及39例无帕金基因突变的患者术后的随访情况。神经外科手术后12至24个月,携带两个帕金基因突变的患者左旋多巴等效剂量显著更低,这表明这些患者从DBS中获益,且可能有更持久的效果。